Nanoscale size control of protein aggregates.

Herein, a novel method to synthesize soluble, sub-micrometer sized protein aggregates is demonstrated by mixing native and denatured proteins without using bacteria and contaminating proteins. Ovalbumin (OVA) is employed as a model protein. The average size of the formed aggregates can be controlled by adjusting the fraction of denatured protein in the sample and it is possible to make unimodal size distributions of protein aggregates. OVA aggregates with a size of ∼95 nm are found to be more immunogenic compared to native OVA in a murine splenocyte proliferation assay. These results suggest that the novel method of engineering size specific sub-micrometer sized aggregates may constitute a potential route to increasing the efficacy of protein vaccines. The protein aggregates may also be promising for use in other applications including the surface functionalization of biomaterials and as industrial catalysis materials.

[1]  Ying Y Hey,et al.  Murine spleen contains a diversity of myeloid and dendritic cells distinct in antigen presenting function , 2012, Journal of cellular and molecular medicine.

[2]  H. Kiyono,et al.  Two Distinct Epitopes on the Ovalbumin 323-339 Peptide Differentiating CD4+T Cells into the Th2 or Th1 Phenotype , 2012, Bioscience, biotechnology, and biochemistry.

[3]  M. Strømme,et al.  Current status and future prospects of nanotechnology in cosmetics , 2012 .

[4]  Esther Vázquez,et al.  Bacterial inclusion bodies: making gold from waste. , 2012, Trends in biotechnology.

[5]  Jian-Zhong Shao,et al.  Toxicity evaluation of biodegradable chitosan nanoparticles using a zebrafish embryo model , 2011, International journal of nanomedicine.

[6]  T. Casale,et al.  Immune modulation for treatment of allergic disease , 2011, Immunological reviews.

[7]  R. Germain,et al.  Protective T cell immunity in mice following protein-TLR7/8 agonist-conjugate immunization requires aggregation, type I IFN, and multiple DC subsets. , 2011, The Journal of clinical investigation.

[8]  Fulin Wu,et al.  Unfolding and refolding details of lysozyme in the presence of β-casein micelles. , 2011, Physical chemistry chemical physics : PCCP.

[9]  A. Espino,et al.  Effectiveness of intranasal vaccination against Angiostrongylus costaricensis using a serine/threonine phosphatase 2 A synthetic peptide and recombinant antigens. , 2010, Vaccine.

[10]  T. Ficht,et al.  Polymeric particles in vaccine delivery. , 2010, Current opinion in microbiology.

[11]  M. Malmsten,et al.  Nanomedicine: reshaping clinical practice , 2010, Journal of internal medicine.

[12]  J. Veciana,et al.  Surface Cell Growth Engineering Assisted by a Novel Bacterial Nanomaterial , 2009 .

[13]  H. Benson,et al.  Pharmaceutical aspects of intranasal delivery of vaccines using particulate systems. , 2009, Journal of pharmaceutical sciences.

[14]  Rakesh K. Kumar,et al.  The "classical" ovalbumin challenge model of asthma in mice. , 2008, Current drug targets.

[15]  A. Renault,et al.  Interfacial properties of heat-treated ovalbumin. , 2007, Journal of colloid and interface science.

[16]  H. Wędrychowicz,et al.  Vaccine potential of inclusion bodies containing cysteine proteinase of Fasciola hepatica in calves and lambs experimentally challenged with metacercariae of the fluke. , 2007, Veterinary parasitology.

[17]  H. Wędrychowicz,et al.  Enteral vaccination of rats against Fasciola hepatica using recombinant cysteine proteinase (cathepsin L1). , 2007, Vaccine.

[18]  M. Løvik,et al.  The allergy adjuvant effect of particles – genetic factors influence antibody and cytokine responses , 2005, BMC Immunology.

[19]  T. Kündig,et al.  Immunity in response to particulate antigen-delivery systems. , 2005, Advanced drug delivery reviews.

[20]  F. Spertini,et al.  Intranasal treatment with ovalbumin but not the major T cell epitope ovalbumin 323–339 generates interleukin‐10 secreting T cells and results in the induction of allergen systemic tolerance , 2004, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[21]  B. Szewczyk,et al.  Inclusion bodies from recombinant bacteria as a novel system for delivery of vaccine antigen by the oral route. , 2004, Immunology letters.

[22]  A. Middelberg,et al.  The influence of molecular variation on protein interactions. , 2003, Biotechnology and bioengineering.

[23]  Hans P Kocher,et al.  The likelihood of aggregation during protein renaturation can be assessed using the second virial coefficient , 2003, Protein science : a publication of the Protein Society.

[24]  A. Villaverde,et al.  Construction and deconstruction of bacterial inclusion bodies. , 2002, Journal of biotechnology.

[25]  R. Kopito,et al.  Aggresomes, inclusion bodies and protein aggregation. , 2000, Trends in cell biology.

[26]  T. Root,et al.  Protein retention in hydrophobic interaction chromatography: modeling variation with buffer ionic strength and column hydrophobicity , 1997 .

[27]  J. Lowe,et al.  The latent membrane protein‐1 in Epstein‐Barr virus‐transformed lymphoblastoid cells is found with ubiquitin‐protein conjugates and heat‐shock protein 70 in lysosomes oriented around the microtubule organizing centre , 1991, The Journal of pathology.

[28]  D. Morrison,et al.  Binding of polymyxin B to the lipid A portion of bacterial lipopolysaccharides. , 1976, Immunochemistry.

[29]  P. Scott.  Development and regulation of cell-mediated immunity in experimental Leishmaniasis , 2003, Immunologic research.